IVF hartmann Holding AG engages in production and supply of medical, pharmaceutical and hygiene products in Switzerland, it offers products such as surgical disposable, disposable dental, first aid, therapeutic plaster, cotton wool, wound care among others. The company operates in four segment wound care, incontinence management, infection management and Other group activities.
1874
316
LTM Revenue n/a
LTM EBITDA n/a
$325M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IVF hartmann has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, IVF hartmann achieved revenue of $192M and an EBITDA of $35.7M.
IVF hartmann expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IVF hartmann valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $178M | $192M | XXX | XXX | XXX |
Gross Profit | $97.3M | $96.6M | XXX | XXX | XXX |
Gross Margin | 54% | 50% | XXX | XXX | XXX |
EBITDA | $28.3M | $35.7M | XXX | XXX | XXX |
EBITDA Margin | 16% | 19% | XXX | XXX | XXX |
Net Profit | $13.5M | $18.3M | XXX | XXX | XXX |
Net Margin | 8% | 10% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, IVF hartmann's stock price is CHF 157 (or $189).
IVF hartmann has current market cap of CHF 377M (or $455M), and EV of CHF 269M (or $325M).
See IVF hartmann trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$325M | $455M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, IVF hartmann has market cap of $455M and EV of $325M.
IVF hartmann's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate IVF hartmann's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for IVF hartmann and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $325M | XXX | XXX | XXX |
EV/Revenue | 1.7x | XXX | XXX | XXX |
EV/EBITDA | 9.1x | XXX | XXX | XXX |
P/E | 18.6x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 15.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIVF hartmann's NTM/LTM revenue growth is n/a
IVF hartmann's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, IVF hartmann's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate IVF hartmann's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for IVF hartmann and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 7% | XXX | XXX | XXX | XXX |
EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
EBITDA Growth | 26% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 42% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IVF hartmann acquired XXX companies to date.
Last acquisition by IVF hartmann was XXXXXXXX, XXXXX XXXXX XXXXXX . IVF hartmann acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was IVF hartmann founded? | IVF hartmann was founded in 1874. |
Where is IVF hartmann headquartered? | IVF hartmann is headquartered in Switzerland. |
How many employees does IVF hartmann have? | As of today, IVF hartmann has 316 employees. |
Is IVF hartmann publicy listed? | Yes, IVF hartmann is a public company listed on SWX. |
What is the stock symbol of IVF hartmann? | IVF hartmann trades under VBSN ticker. |
When did IVF hartmann go public? | IVF hartmann went public in 2012. |
Who are competitors of IVF hartmann? | Similar companies to IVF hartmann include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
What is the current market cap of IVF hartmann? | IVF hartmann's current market cap is $455M |
What is the current revenue growth of IVF hartmann? | IVF hartmann revenue growth between 2023 and 2024 was 7%. |
Is IVF hartmann profitable? | Yes, IVF hartmann is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.